-
NMPA Announcement on Adopting ICH Guideline E9 (R1)
2021-01-25
To keep pace with the international technical standards for drug registration, the NMPA has decided to adopt the ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) Guideline E9 (R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials.
-
NMPA Announcement on Adopting ICH Guidelines S5 (R3) and S11
2021-01-25
To keep pace with the international technical standards for drug registration, the NMPA has decided to adopt two guidelines of ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use).
-
NMPA Announcement on the Application of ICH Guideline E9 (R1): Estimands and Sensitivity Analysis in Clinical Trials
2021-01-21
To keep pace with the international technical standards for drug registration, the NMPA has decided to recommend the application of ICH Guideline E9 (R1): Estimands and Sensitivity Analysis in Clinical Trials.
-
NMPA Announcement on Revising the Package Inserts of Sulfasalazine Preparations
2021-01-14
To further protect public medication safety, the NMPA decided to revise the package inserts of Sulfasalazine Preparations. The relevant issues are hereby announced as follows.
-
NMPA Announcement on the Cancellation of Registration Certificates for Phenolphthalein Tablets and Phenolphthalein Buccal Tablets
2021-01-14
The NMPA therefore decided the immediate cessation of production, sales and use of the two drugs in China with their registration certificates (drug approval number) revoked forthright.
-
NMPA Announcement on Issuing the Provisions for the Change Management of Post-approval Drugs (Interim)
2021-01-13
The NMPA organized to formulate of the Provisions for Change Management of Post-approval Drugs (Interim), is hereby promulgated and shall go into effect as of January 12, 2021.
